Patient characteristics
| Diagnosis . | ALL . | CML . |
|---|---|---|
| No. of patients | 15 | 7 |
| Imatinib therapy before HCT, no. | 14 | 7 |
| Disease phase, no. | ||
| CR1, CR2 | 14, 1 | — |
| AP, CP2, CP3, BC remission | — | 2, 2, 2, 1 |
| Median age, y (range) | 37 (4-49) | 44 (24-62) |
| Sex, male/female | 7/8 | 3/4 |
| Donor, no. | ||
| Related | 6 | 2 |
| Unrelated | 9 | 5 |
| Stem cell source, no. | ||
| Peripheral blood | 10 | 6 |
| Marrow | 4 | 1 |
| Cord blood | 1 | 0 |
| Conditioning, no. | ||
| TBI-based | 15 | 2 |
| Non-TBI-based | 0 | 5 |
| GVHD prophylaxis, no. | ||
| Methotrexate/cyclosporine | 6 | 4 |
| Methotrexate/tacrolimus | 5 | 2 |
| Sirolimus/tacrolimus with or without methotrexate | 3 | 0 |
| Mycophenolate mofetil/tacrolimus | 0 | 1 |
| Methylprednisolone/cyclosporine/ATG | 1 | 0 |
| Intrathecal methotrexate after HCT, no. | ||
| Yes | 10 | 3 |
| No | 5 | 4 |
| Cytomegalovirus, no. | ||
| No reactivation | 12 | 6 |
| Ganciclovir/valganciclovir before day 90 | 4* | 1 |
| Diagnosis . | ALL . | CML . |
|---|---|---|
| No. of patients | 15 | 7 |
| Imatinib therapy before HCT, no. | 14 | 7 |
| Disease phase, no. | ||
| CR1, CR2 | 14, 1 | — |
| AP, CP2, CP3, BC remission | — | 2, 2, 2, 1 |
| Median age, y (range) | 37 (4-49) | 44 (24-62) |
| Sex, male/female | 7/8 | 3/4 |
| Donor, no. | ||
| Related | 6 | 2 |
| Unrelated | 9 | 5 |
| Stem cell source, no. | ||
| Peripheral blood | 10 | 6 |
| Marrow | 4 | 1 |
| Cord blood | 1 | 0 |
| Conditioning, no. | ||
| TBI-based | 15 | 2 |
| Non-TBI-based | 0 | 5 |
| GVHD prophylaxis, no. | ||
| Methotrexate/cyclosporine | 6 | 4 |
| Methotrexate/tacrolimus | 5 | 2 |
| Sirolimus/tacrolimus with or without methotrexate | 3 | 0 |
| Mycophenolate mofetil/tacrolimus | 0 | 1 |
| Methylprednisolone/cyclosporine/ATG | 1 | 0 |
| Intrathecal methotrexate after HCT, no. | ||
| Yes | 10 | 3 |
| No | 5 | 4 |
| Cytomegalovirus, no. | ||
| No reactivation | 12 | 6 |
| Ganciclovir/valganciclovir before day 90 | 4* | 1 |
Numbers indicate numbers of patients unless otherwise indicated.
CR indicates complete remission; AP, accelerated phase; CP, chronic phase; BC, blast crisis; TBI, total body irradiation; ATG, antithymocyte globulin; —, not applicable.
One patient did not develop reactivation of CMV but was receiving either valganciclovir or placebo as part of a randomized CMV prophylaxis study.